P2, N=40, Completed, Beijing Wehand-Bio Pharmaceutical Co., Ltd | Phase classification: P1 --> P2

Moreover, PAX alone significantly upregulated CASP1 and CASP3 expression, while co-treatment with SA significantly downregulated these genes. These findings highlight the protective role of SA in reducing PAX-induced toxicity, particularly in hepatic tissues, suggesting that SA could be a potential adjunct therapy for minimizing chemotherapy-related side effects.

P=N/A, N=23, Terminated, University Hospital, Brest | N=214 --> 23 | Unknown status --> Terminated

Given the clinical severity, inpatient treatment was promptly initiated with trastuzumab and pertuzumab every three weeks, combined with weekly paclitaxel at a 50% dose reduction. In carefully selected patients, early and sustained HER2-directed therapy can lead to meaningful clinical recovery when options appear limited. Such cases help bridge the evidence gap for this high-risk group and may inform future therapeutic considerations.

P2, N=60, Recruiting, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

P=N/A, N=1000, Active, not recruiting, Norfolk and Norwich University Hospitals NHS Foundation Trust | Trial completion date: Jan 2027 --> Dec 2031 | Trial primary completion date: Jan 2027 --> Dec 2031

Combination therapy with paclitaxel further reduced viability to 9.4 ± 1.8% (p < 0.001)...Western blot analysis confirmed elevated cleaved caspase-3, cleaved PARP, Granzyme B, FasL, Phospho-NF-κB-p65 and reduced Ki-67 and PDL1 in NK-Exo-CE + PTX tumors. Collectively, electro-hypoxic bioreactor conditioning enables scalable NK-exosome production without compromising physicochemical integrity or antitumor efficacy, addressing a key translational barrier in extracellular vesicle therapeutics.

P1, N=12, Suspended, City of Hope Medical Center | Recruiting --> Suspended

A co-delivery therapeutic strategy combining the pan-HDAC inhibitor belinostat (PXD101) with paclitaxel (PTX) was developed and evaluated in patient-derived cisplatin-resistant organoids and a platinum-refractory patient-derived xenograft (PDX) model. Modulation of p21 influenced cell-cycle re-entry, senescence burden, and responsiveness to PTX. These findings define an HDAC-p21-senescence axis that sustains chemoresistance in bladder cancer and provide preclinical evidence supporting combined epigenetic and antimitotic therapy as a strategy to overcome acquired drug tolerance.

This case highlights the diagnostic complexity of PSA in young adults presenting with unexplained anemia and splenic lesions. Bone marrow findings may be misleadingly reactive, underscoring the importance of histopathological confirmation of splenic tissue. Early recognition and prompt surgical intervention remain critical given the aggressive nature and poor prognosis of this malignancy.

P2, N=40, Active, not recruiting, City of Hope Medical Center | Trial completion date: Apr 2026 --> Mar 2027

P=N/A, N=34, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027